Production (Stage)
Alzamend Neuro, Inc.
ALZN
$3.65
$0.092.53%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 590.30K | 1.05M | 755.80K | 666.60K | 751.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.04M | 1.36M | 962.40K | 850.10K | 2.66M |
| Operating Income | -1.04M | -1.36M | -962.40K | -850.10K | -2.66M |
| Income Before Tax | -1.04M | -1.36M | -974.40K | -851.50K | -2.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.04M | -1.36M | -974.40K | -851.50K | -2.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.04M | -1.36M | -974.40K | -851.50K | -2.66M |
| EBIT | -1.04M | -1.36M | -962.40K | -850.10K | -2.66M |
| EBITDA | -1.02M | -1.35M | -949.70K | -837.40K | -2.65M |
| EPS Basic | -1.70 | -3.61 | -11.27 | -11.14 | -33.97 |
| Normalized Basic EPS | -1.06 | -2.17 | -7.05 | -6.96 | -21.23 |
| EPS Diluted | -1.70 | -3.61 | -11.27 | -11.14 | -33.97 |
| Normalized Diluted EPS | -1.06 | -2.17 | -7.05 | -6.96 | -21.23 |
| Average Basic Shares Outstanding | 613.10K | 392.40K | 86.40K | 76.50K | 78.40K |
| Average Diluted Shares Outstanding | 613.10K | 392.40K | 86.40K | 76.50K | 78.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |